We are pleased to announce that the USDMF for Desvenlafaxine Succinate has been submitted to the USFDA.
Intellipharmaceutics` Generic Desvenlafaxine Receives Approval in US
Yichang Humanwell's Generic Desvenlafaxine Succinate Receives Approval in US
The company has received approval from the US Food and Drug Administration (USFDA) to market its product which is a generic equivalent of Wyeth Pharma Inc's Pristiq tablets, Alembic Pharmaceuticals said in a regulatory filing.
Zydus Pharm’s Generics Desvenlafaxine Succinate Receives Approval In US
Pristiq itself was a drug launched to protect Pfizer sales from the patent loss on a preceding antidepressant, Effexor. Pristiq was first developed by Wyeth before it merged into Pfizer in 2009 to create the drug giant it is today.
Drug firm Alembic PharmaceuticalsBSE 0.98 % today said its partner Breckenridge Pharma has launched desvenlafaxine succinate extended release tablets used in treatment of major depressive disorder.
Pharma major LupinBSE 0.48 % today launched an anti-depression generic drug Pristiq in the US.
Under the terms of the 10-year agreement, Intellipharmaceutics will receive a non-refundable upfront payment of US$3 million in October 2016. In addition, the agreement also provides for the Company to have a long-term profit sharing arrangement with respect to the licensed products. Intellipharmaceutics has agreed to manufacture and supply the licensed products exclusively for Mallinckrodt, and Mallinckrodt has agreed that Intellipharmaceutics will be its sole supplier of the licensed products marketed in the U.S.
Roxane`s Generic Desvenlafaxine Succinate(204083) approved in US as antidepressant